/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from its Phase 2b FRONTIER 1 clinical trial...

Related Keywords

Spring House , British Columbia , Canada , Japan , United States , United Kingdom , Montreal , Quebec , Germany , Spain , Americans , Robert Bissonnette , Lloyd Miller , Bridget Kimmel , Janssen Research Development , Exchange Commission , Janssen Biotech Inc , National Psoriasis Foundation , Patient Preference , Janssen Biotech For The Continued Development , Janssen Pharmaceutical Companies , Johnson , Everyday Health , Truven Health Analytics Data , Collaboration Agreement With Protagonist Therapeutics Inc , Companies Of Johnson , Decision Resources Internal Claims Research , Janssen Pharmaceutical Companies Of Johnson , None Of Janssen Research Development , Janssen Scientific Affairs , Psoriasis Area , Severity Index , Chief Executive Officer , Medical Director , Lead Investigator , Vice President , Immunodermatology Disease Area Stronghold Leader , Janssen Research , Global Assessment , Psoriasis Symptoms , Signs Diary , Dermatology Life Quality Index , Plaque Psoriasis , Protagonist Therapeutics , Janssen Biotech , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Dose Ranging Study , Moderate To Severe Plaque Psoriasis , In Class Oral Peptide Systemically Targeting , Cell Penetration , Protagonist Reports Positive Results , Pre Clinical Studies , Decision Resources , Internal Claims , Truven Health Analytics , Patient Preference Survey , Accessed June , Protagonist Therapeutics Announces Amendment , Continued Development , Protagonist Therapeutics Announces Positive , Topline Results , Janssen Enters Into Worldwide Exclusive License , For The Oral , Antagonist Drug Candidate For The Treatment , Inflammatory Bowel ,